肝动脉化疗栓塞术后患者发生急性中重度腹痛的危险因素分析

doi:10.3761/j.issn.0254-1769.2020.03.020

摘要/Abstract

摘要：

目的探讨肝动脉化疗栓塞（transarterial chemoembolization,TACE）术后患者急性中重度腹痛的发生规律及危险因素,初步建立TACE术后腹痛预测模型。方法采用回顾性队列研究法,收集浙江省某三级甲等医院2018年1月—6月期间行TACE的原发性肝癌患者,根据是否发生急性中重度腹痛分为腹痛组和非腹痛组,对两组的资料进行单因素分析,将有统计学意义的因素进行Logistic回归分析,初步建立预测模型,并分析该模型的预测效果。结果共纳入患者367例,共行425次TACE,统计结果显示,预防性TACE术后均未发生急性中重度腹痛;肝内肿瘤多发（肿瘤病灶数量≥3个）、TACE术后腹痛史、手术方式和TACE次数是TACE术后发生急性中重度腹痛的独立预测因子,最终建立的预测模型受试者操作特征曲线下面积为0.794（95%CI为0.736~0.852）,Hosmer-Lemeshow检验结果显示,χ ²=2.205,P=0.974。结论本研究构建的预测模型能较好地预测TACE术后急性中重度腹痛发生的风险,可为医护人员实施预防性疼痛管理措施提供参考。

关键词: 肝肿瘤, 化学栓塞, 治疗性, 腹痛, 外科护理, 危险因素

Abstract:

Objective To observe and investigate the occurrence regularity and risk factors of acute moderate and severe abdominal pain after transarterial chemoembolization（TACE）,and to establish a prediction model of postoperative pain after TACE. Methods Retrospective cohort study was used to collect patients with primary liver cancer treated by TACE from January to June 2018 in a hospital. The patients were divided into abdominal pain group and non-pain group. The data of 2 groups was analyzed by univariate analysis. The statistically significant factors were analyzed by multivariate Logistic regression analysis,and the pain prediction model was established. The model evaluation and internal verification were carried out. Results A total of 367 patients were enrolled in this study and 425 times of TACE were performed in half a year. The statistical results showed that no moderate and severe abdominal pain occurred after preventive TACE. Multiple liver tumors（the number of tumors≥3）,a history of pain after TACE,transarterial chemoembolization with drug-eluting beads and a low number of TACE were independent predictors of acute moderate and severe abdominal pain. The area under the predicted ROC curve was 0.794（95%CI0.736~0.852）,and the test result of Hosmer-Lemeshow showed that χ ²=2.205,P=0.974. Conclusion The prediction model constructed in this study can predict acute moderate and severe abdominal pain after TACE,and can provide references for medical staff with management measures of preventive pain.

Key words: Liver Neoplasms, Chemoembolizationn, Therapeutic, Abdominal Pain, Surgical Nursing Care, Risk factors

卞丽芳, 高蓓蕾, 张晟, 詹冬娣, 葛国梅, 叶婷婷, 郑燕. 肝动脉化疗栓塞术后患者发生急性中重度腹痛的危险因素分析[J]. 中华护理杂志, 2020, 55(3): 416-421.

BIAN Lifang, GAO Beilei, ZHANG Sheng, ZHAN Dongdi, GE Guomei, YE Tingting, ZHENG Yan. Risk factors and predictive analysis of acute severe abdominal pain after transarterial chemoembolization[J]. Chinese Journal of Nursing, 2020, 55(3): 416-421.

图/表 3

参考文献 23

[1]	中国医师协会介入医师分会. 中国肝细胞癌经动脉化疗栓塞治疗临床实践指南[J]. 中华放射学杂志, 2019,53(4):246-255.
[2]	滕皋军. 首部指南助推肝癌介入治疗规范化[EB/OL].( 2018-07-12)[2019-06-29]. http://www. sohu. com/a/240698530_377345.
[3]	陈瑜, 黄道琼, 李海燕 , 等. 肝癌栓塞术后疼痛患者择时给药时间点的改进及效果[J]. 中华护理杂志, 2019,54(3):393-395.
[4]	Zhou B, Wang JH, Yan ZP , et al. Liver cancer:effects,safety,and cost-effectiveness of controlled-release oxycodone for pain control after TACE[J]. Radiology, 2012,262(3):1014-1021.
[5]	孟永斌, 陈红云, 翟笑枫 , 等. 原发性肝癌患者肝动脉化疗栓塞术后疼痛的影响因素分析[J]. 肿瘤学杂志, 2013,19(9):722-725.
[6]	来鸣, 周云仙, 张艳阳 . 治疗性触摸应用于肝癌经导管动脉化疗栓塞术后疼痛控制的研究[J]. 中华护理杂志, 2006,41(3):198-201.
[7]	罗君, 邵国良, 郑家平 , 等. 原发性肝癌肝动脉化疗栓塞术后腹痛的发生规律及影响因素[J]. 介入放射学杂志, 2017,26(7):613-617.
[8]	Benzakoun J, Ronot M, Lagadec M , et al. Risks factors for severe pain after selective liver transarterial chemoembolization[J]. Liver Int, 2017,37(4):583-591.
[9]	国家卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范(2017年版)[J]. 中华外科消化杂志, 2017,16(7):635-647.
[10]	成燕, 童莺歌, 刘敏君 . 术后活动性疼痛护理评估对疼痛管理质量的影响[J]. 中华护理杂志, 2015,50(8):924-928.
[11]	臧爽, 徐阳, 梁松年 . 原发性肝癌患者经肝动脉化疗栓塞术后住院天数影响因素的多元线性回归分析[J]. 介入放射学杂志, 2015,24(1):80-83.
[12]	Khalaf MH, Sundaram V, AbdelRazek Mohammed MA, et al. A predictive model for postembolization syndrome after transarterial hepatic chemoembolization of hepatocellular carcinoma[J]. Radiology, 2019,290(1):254-261.
[13]	Dhand S, Gupta R . Hepatic transcatheter arterial chemoem-bolization complicated by postembolization syndrome[J]. Semin Intervent Radiol, 2011,28(2):207-211.
[14]	Lv N, Kong YN, Mu LW , et al. Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma:a prospective randomized trial[J]. Eur Radiol, 2016,26(10):3492-3499.
[15]	Guo JG, Zhao LP, Rao YF , et al. Novel multimodal analgesia regimen improves post-TACE pain in patients with hepatocellular carcinoma[J]. HBPD INT, 2018,17(6):510-516.
[16]	饶跃峰, 赵璐萍, 王融溶 , 等. 多模式镇痛在肝癌患者肝动脉化疗栓塞术中的应用[J]. 中华肝胆外科杂志, 2017,23(6):375-379.
[17]	支梦佳, 魏兴梅, 高翔 , 等. 我国阿片类镇痛药物临床使用现状分析[J]. 药物流行病学杂志, 2018,27(6):400-405.
[18]	丁以锟, 吕维富, 周春泽 , 等. 术后预防性肝动脉化疗栓塞对肝癌患者生存的影响及预后相关因素分析[J]. 介入放射学杂志, 2014,23(4):299-302.
[19]	Golfieri R, Giampalma E, Renzulli M , et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma[J]. Br J Cancer, 2014,111(2):255-264.
[20]	Poon RT, Tso WK, Pang RW , et al. A phase I / II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead[J]. Clin Gastroenterol Hepatol, 2007,5(9):1100-1108.
[21]	Baur J, Ritter CO, Germer CT , et al. Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma[J]. Hepat Med, 2016,8:69-74.
[22]	陈刚 . CalliSpheres载药微球经动脉化疗栓塞治疗不可切除原发性肝癌的临床研究[D]. 杭州:浙江大学, 2017.
[23]	Zhang X, Zhou J, Zhu DD , et al. CalliSpheres drug-eluting beads(DEB) transarterial chemoembolization(TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments:a result from CTILC study[J]. Clin Transl Oncol, 2019,21(2):167-177.